The record that decides the next step
For non-small cell lung cancer, the pathology report is not a formality. It establishes the tissue type and, with the biomarker results, whether a targeted therapy or immunotherapy is potentially relevant. If the original pathology report or the biomarker panel is absent, a clinician reviewing the case in China may be able to describe the general situation but cannot confirm which systemic options fit this specific tumour.
This matters because the same scan appearance can correspond to different tumour biology. A plan built on an incomplete file may be provisional. That is not a reason to delay necessary local care, but it is a reason to ask exactly which document is missing and what decision it would unlock.
A practical request: ask the hospital team to list the missing items in writing, with the reason each one matters. That list becomes the checklist for your records request, rather than a general appeal for everything.
Biomarker reports: what their absence leaves open
Biomarker testing looks for specific features in the tumour tissue that can guide whether certain targeted drugs or immunotherapies are worth discussing. If the report exists but is not in the file, or if testing was never completed, the treating team cannot confirm whether those options are relevant for this patient.
The distinction is important. A missing biomarker report does not automatically mean a test must be repeated. Sometimes the original laboratory report can be retrieved; sometimes the tissue block or slides can be requested and re-examined. Which route applies is a clinical and laboratory question for the receiving hospital, not something to assume in advance.
When you contact the original hospital or laboratory, ask for the full report with the method used, the results, and the date. A one-line summary is less useful than the complete document. If the original tissue is available, ask whether it can be released and how.
Previous cancer therapy: why the treatment history changes the question
A clinician assessing a patient who has already received cancer treatment needs to know what was given, when, at what dose, and how the disease responded. Without that history, it is difficult to judge whether a previous option was ineffective, stopped for side effects, or was never completed. This is the part of the file that can decide whether a drug can be reconsidered, whether a different line of therapy makes sense, or whether the question is really about something else entirely.
Consider what a single line of treatment can hide. A record that says only 'chemotherapy' does not tell the next team which agents were used, whether the disease shrank, stayed stable or progressed, or whether treatment stopped because it failed or because the patient could not tolerate it. Those are different clinical situations, and they point in different directions. A drug that was stopped for toxicity may still be an option at a reduced dose; a drug that was stopped because the disease progressed is a different question. Without the dates and the reason, the treating team is working from a conclusion with no supporting detail.
The same applies to targeted therapy and immunotherapy. If a patient received a targeted drug, the next team needs to know which molecular feature it was matched to, when it started, how long it worked, and why it stopped. If a patient received immunotherapy, the record should show the regimen, the number of cycles, and whether any immune-related side effect occurred. A prior immune-related adverse event can change how the next team weighs immunotherapy again, and that detail is easy to lose in a discharge summary that says only 'immunotherapy completed'.
Response assessment matters as much as the treatment list. If imaging was used to judge whether a treatment was working, the reports and, where possible, the images themselves help the next team understand the pace of the disease. A written note that says 'stable disease' without the scan it came from is less useful than the scan report with dates. If the previous centre used a different staging system or a different reporting style, the original documents still carry more information than a translated summary.
There is also a practical gap that patients often discover late: treatment given at more than one hospital. If part of the therapy was delivered elsewhere, or if a clinical trial was involved, the main file may be incomplete without the patient realising it. Trial records in particular may sit with a sponsor or a research office rather than the treating hospital, and the request route is different. Ask the previous team whether any part of the treatment was delivered under a trial protocol, and if so, who holds those records.
When you request a treatment summary, be specific about what you need. Ask for regimen names and the molecular feature each targeted drug was matched to, start and stop dates for every line, the response assessment at each decision point, and the documented reason for any change or stop. Ask for the pathology and biomarker reports that supported those choices, not just the treatment list. If the previous centre can provide a chronological summary signed by the treating clinician, that is more useful than a stack of unrelated pages, because it shows the sequence and the reasoning.
One more distinction is worth making. A treatment history is not the same as a treatment recommendation. Knowing what was tried does not tell the next team what to do; it tells them what has already been answered and what remains open. A patient who arrives with a clear sequence of treatments, responses and reasons for stopping gives the next clinician a real basis for discussion. A patient who arrives with a list of drug names but no dates or outcomes leaves the most important questions unanswered, and the next step may be a request for records rather than a plan.
If the previous centre is slow to respond, or if the records are in another language, ask the receiving hospital what it needs first. A short, well-organised summary of the treatment sequence may be enough to start a review, even before the full archive arrives. The goal is not to send everything at once; it is to send the documents that answer the question the treating team is actually asking.
Imaging and staging: what a report alone may not settle
Staging describes how far the cancer has spread and shapes whether surgery, radiotherapy, systemic therapy or a combination is discussed. Staging is usually built from imaging plus pathology, and a written report without the images can leave the treating team unable to confirm certain findings.
If a PET-CT or CT report is available but the images are not, the receiving hospital may still be able to review the case, but it may need to repeat or supplement imaging. Whether that is necessary is a clinical decision for the treating team, based on what they can see and what they need.
When requesting imaging, ask for the reports and the image files in a standard format, plus the date of each study. Ask the receiving hospital what format and what coverage they need before you send anything.
Local and systemic options: what the file must support
Lung cancer care can involve surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or combinations. Which of these is discussed depends on the stage, the pathology, the biomarker results, the patient's general condition, and what has already been tried.
A lung lobectomy removes a lung lobe; it is different from removal of an entire lung. Whether a lobectomy or another operation is even relevant depends on the staging and the pathology, which is why those records come first. The treating team decides suitability, not the patient's file alone.
If the file is incomplete, the honest position is that some options cannot yet be confirmed or excluded. Ask the team to state which decisions are pending and which records would resolve them. That is more useful than a general opinion built on partial information.
How to ask, and what to expect back
Start with a short summary: the diagnosis as you understand it, the main question, and the records you already have. You do not need to send a complete archive at first contact. A brief summary is enough for an initial review of what is missing and what the next step could be.
When you ask a hospital or a coordination service, be specific. Ask which documents are needed, in what language, and whether certified translation is required. Ask whether the team can work from copies or needs originals. Ask what a preliminary reply can and cannot confirm.
Expect that a records-based opinion is not the same as a final treatment plan. A remote review can clarify the situation and identify gaps, but eligibility for a specific treatment, and hospital acceptance, are decided by the treating hospital after it has what it needs.
If you would like help requesting records, arranging interpretation, or asking a hospital for a specialist appointment, ChinaSpecialistCare can coordinate that practical side. An initial enquiry is free, and a proxy consultation is optional, not a prerequisite.
The next step is simple: write down the one question you most need answered, list the records you have, and ask the receiving team which missing document would change their answer. Then request that document specifically.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.